Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China

Effectiveness and Safety of Palbociclib Plus Endocrine Therapy in Patients with Advanced Breast Cancer: A Multi-Center Study in China

Background: Palbociclib has been approved for marketing in China. However, its effectiveness, safety, and latent variables in the Chinese population require further investigation. Methods: Information was retrieved from 397 patients with metastatic breast cancer (mBC) who received at least two cycle...

Full description

Bibliographic Details
Main Authors:	Xinyu Wu, Nan Jin, Hongfei Gao, Min Yan, Qianjun Chen, Tao Sun, Chunfang Hao, Yanxia Zhao, Xinhua Han, Yueyin Pan, Xiang Huang, Wei Li, Kun Wang, Yongmei Yin
Format:	Article
Language:	English
Published:	MDPI AG 2023-09-01
Series:	Cancers
Subjects:	palbociclib metastatic breast cancer real-world study
Online Access:	https://www.mdpi.com/2072-6694/15/17/4360

Similar Items

Real-world comparative effectiveness of palbociclib plus letrozole versus letrozole in older patients with metastatic breast cancer
by: Hope S. Rugo, et al.
Published: (2023-06-01)

Real-world treatment patterns and effectiveness of palbociclib plus an aromatase inhibitor in patients with metastatic breast cancer aged 75 years or older
by: Adam Brufsky, et al.
Published: (2023-09-01)

Palbociclib in metastatic breast cancer: current evidence and real-life data
by: Francesco Serra, et al.
Published: (2019-07-01)

Population Pharmacokinetics of Palbociclib in a Real-World Situation
by: Bernard Royer, et al.
Published: (2021-02-01)

Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
by: Adam Brufsky, et al.
Published: (2022-07-01)

Real-world treatment patterns and clinical outcomes in patients receiving palbociclib combinations for HR+/HER2– advanced/metastatic breast cancer in Japan: Results from the IRIS study
by: Katie Mycock, et al.
Published: (2022-01-01)

Real-World Palbociclib Use in HR+/HER2− Advanced Breast Cancer in Canada: The IRIS Study
by: Katie Mycock, et al.
Published: (2021-01-01)

Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network
by: Jeanna Wallenta Law, et al.
Published: (2022-02-01)

Efficacy and activity of treatments after progression from palbociclib plus endocrine therapy in patients with HR+/HER2– metastatic breast cancer: a prospective, monocentric study
by: Raffaella Palumbo, et al.
Published: (2024-02-01)

Real-world safety of palbociclib in breast cancer patients in the United States: a new user cohort study
by: Daniel C. Beachler, et al.
Published: (2021-01-01)

Economic Evaluation for Palbociclib Plus Fulvestrant vs Ribociclib Plus Fulvestrant and Abemaciclib Plus Fulvestrant in Endocrine-Resistant Advanced or Metastatic Breast Cancer in Italy
by: Colombo GL, et al.
Published: (2023-03-01)

Real-world palbociclib effectiveness in patients with metastatic breast cancer: Focus on neutropenia-related treatment modification strategies and clinical outcomes
by: Mariska Q.N. Hackert, et al.
Published: (2023-01-01)

Treatment patterns, effectiveness, and patient‐reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real‐world study
by: Lesang Shen, et al.
Published: (2022-11-01)

Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer
by: B. Porte, et al.
Published: (2020-12-01)

Identification of a Panel of miRNAs Associated with Resistance to Palbociclib and Endocrine Therapy
by: Rosalba Torrisi, et al.
Published: (2024-01-01)

Palbociclib Adherence and Persistence in Patients with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer
by: Engel-Nitz NM, et al.
Published: (2023-04-01)

Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia
by: James Sun, et al.
Published: (2021-11-01)

Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment
by: Cheng Liu, et al.
Published: (2022-08-01)

Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval
by: J. K. Kish, et al.
Published: (2018-05-01)

Innovations in practice. 5 years of palbociclib experience in the Russian Federation. Overview of web-conference took place on 8 October 2021
by: Board Editorial
Published: (2021-12-01)

Risk Factors for Palbociclib-Induced Early Developing Neutropenia in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
by: Yeonhong Lee, et al.
Published: (2023-05-01)

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial
by: Lorenzo Rossi, et al.
Published: (2019-05-01)

Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China
by: Jiao Yang, et al.
Published: (2023-01-01)

Palbociclib Combined with an Aromatase Inhibitor in Patients with Breast Cancer with Lung or Liver Metastases in US Clinical Practice
by: Adam Brufsky, et al.
Published: (2023-11-01)

First-Line Treatment with a Cyclin-Dependent Kinase 4/6 Inhibitor Plus an Aromatase Inhibitor for Metastatic Breast Cancer in Alberta
by: Carla P. Amaro, et al.
Published: (2021-06-01)

Palbociclib in combination with aromatase inhibitors in patients ≥ 75 years with oestrogen receptor-positive, human epidermal growth factor receptor 2 negative advanced breast cancer: A real-world multicentre UK study
by: Salma El Badri, et al.
Published: (2021-12-01)

Does Proton Pump Inhibitors Decrease the Efficacy of Palbociclib and Ribociclib in Patients with Metastatic Breast Cancer?
by: Hatice Odabas, et al.
Published: (2023-03-01)

Oral ulcers in patients treated with palbociclib: a case report
by: Alande Cédric, et al.
Published: (2018-06-01)

Pharmacokinetic/Pharmacodynamic Model of Neutropenia in Real-Life Palbociclib-Treated Patients
by: Alexandre Le Marouille, et al.
Published: (2021-10-01)

Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer
by: Soohyeon Lee, et al.
Published: (2022-04-01)

Determination of palbociclib by high performance liquid chromatography
by: Xiaodong SHI, et al.
Published: (2017-08-01)

Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism
by: Maysa Abu-Khalaf, et al.
Published: (2022-06-01)

The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer
by: Fulbert Fu, et al.
Published: (2022-03-01)

Real-world treatment patterns of subsequent therapy after palbociclib in patients with advanced breast cancer in Japan
by: Masataka Sawaki, et al.
Published: (2023-08-01)

Palbociclib in the treatment of recurrent ovarian cancer
by: Dai Wee Lee, et al.
Published: (2020-11-01)

NEW STRATEGY FOR DRUG TREATMENT OF LUMINAL HER2-NEGATIVE METASTATIC BREAST CANCER
by: E. V. ARTAMONOVA
Published: (2017-06-01)

Efficacy of Palbociclib and Endocrine Treatment in Heavily Pretreated Hormone Receptor-positive/HER2-negative Advanced Breast Cancer: Retrospective Multicenter Trial
by: Atakan Demir, et al.
Published: (2020-03-01)

Palbociclib in the first line combination hormone therapy of HER2- negative metastatic hormone-dependent breast cancer. Clinical follow-up
by: M. A. Frolova, et al.
Published: (2018-07-01)

Two Novel Palbociclib-Resorcinol and Palbociclib-Orcinol Cocrystals with Enhanced Solubility and Dissolution Rate
by: Chenxin Duan, et al.
Published: (2021-12-01)

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer
by: Perrine Courlet, et al.
Published: (2022-06-01)